222 related articles for article (PubMed ID: 29454624)
41. Use of the Flory-Huggins theory to predict the solubility of nifedipine and sulfamethoxazole in the triblock, graft copolymer Soluplus.
Altamimi MA; Neau SH
Drug Dev Ind Pharm; 2016 Mar; 42(3):446-455. PubMed ID: 26266965
[TBL] [Abstract][Full Text] [Related]
42. An investigation of nifedipine miscibility in solid dispersions using Raman spectroscopy.
Keratichewanun S; Yoshihashi Y; Sutanthavibul N; Terada K; Chatchawalsaisin J
Pharm Res; 2015 Jul; 32(7):2458-73. PubMed ID: 25673042
[TBL] [Abstract][Full Text] [Related]
43. Spray-Drying, Solvent-Casting and Freeze-Drying Techniques: a Comparative Study on their Suitability for the Enhancement of Drug Dissolution Rates.
De Mohac LM; Caruana R; Cavallaro G; Giammona G; Licciardi M
Pharm Res; 2020 Feb; 37(3):57. PubMed ID: 32076880
[TBL] [Abstract][Full Text] [Related]
44. Stability-enhanced hot-melt extruded amorphous solid dispersions via combinations of Soluplus® and HPMCAS-HF.
Alshahrani SM; Lu W; Park JB; Morott JT; Alsulays BB; Majumdar S; Langley N; Kolter K; Gryczke A; Repka MA
AAPS PharmSciTech; 2015 Aug; 16(4):824-34. PubMed ID: 25567525
[TBL] [Abstract][Full Text] [Related]
45. Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate.
Hugo M; Kunath K; Dressman J
Drug Dev Ind Pharm; 2013 Feb; 39(2):402-12. PubMed ID: 22591213
[TBL] [Abstract][Full Text] [Related]
46. Molecular interaction between glimepiride and Soluplus®-PEG 4000 hybrid based solid dispersions: Characterisation and anti-diabetic studies.
Reginald-Opara JN; Attama A; Ofokansi K; Umeyor C; Kenechukwu F
Int J Pharm; 2015 Dec; 496(2):741-50. PubMed ID: 26581773
[TBL] [Abstract][Full Text] [Related]
47. Amorphous Solid Dispersions of Felodipine and Nifedipine with Soluplus®: Drug-Polymer Miscibility and Intermolecular Interactions.
Sarpal K; Munson EJ
J Pharm Sci; 2021 Apr; 110(4):1457-1469. PubMed ID: 33359813
[TBL] [Abstract][Full Text] [Related]
48. Investigation of phase diagrams and physical stability of drug-polymer solid dispersions.
Lu J; Shah S; Jo S; Majumdar S; Gryczke A; Kolter K; Langley N; Repka MA
Pharm Dev Technol; 2015 Jan; 20(1):105-17. PubMed ID: 25113671
[TBL] [Abstract][Full Text] [Related]
49. Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.
Liu P; Zhou JY; Chang JH; Liu XG; Xue HF; Wang RX; Li ZS; Li CS; Wang J; Liu CZ
Drug Des Devel Ther; 2020; 14():2959-2975. PubMed ID: 32801637
[TBL] [Abstract][Full Text] [Related]
50. Effect of Compression on the Molecular Arrangement of Itraconazole-Soluplus Solid Dispersions: Induction of Liquid Crystals or Exacerbation of Phase Separation?
Singh A; Bharati A; Frederiks P; Verkinderen O; Goderis B; Cardinaels R; Moldenaers P; Van Humbeeck J; Van den Mooter G
Mol Pharm; 2016 Jun; 13(6):1879-93. PubMed ID: 27092396
[TBL] [Abstract][Full Text] [Related]
51. Bile acid transporter mediated STC/Soluplus self-assembled hybrid nanoparticles for enhancing the oral drug bioavailability.
Zhang S; Cui D; Xu J; Wang J; Wei Q; Xiong S
Int J Pharm; 2020 Apr; 579():119120. PubMed ID: 32035254
[TBL] [Abstract][Full Text] [Related]
52. Solid state drug-polymer miscibility studies using the model drug ABT-102.
Jog R; Gokhale R; Burgess DJ
Int J Pharm; 2016 Jul; 509(1-2):285-295. PubMed ID: 27265312
[TBL] [Abstract][Full Text] [Related]
53. Interdependence of particle properties and bulk powder behavior of indomethacin in quench-cooled molten two-phase solid dispersions.
Semjonov K; Salm M; Lipiäinen T; Kogermann K; Lust A; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
Int J Pharm; 2018 Apr; 541(1-2):188-197. PubMed ID: 29481945
[TBL] [Abstract][Full Text] [Related]
54. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
55. Solvent-shift strategy to identify suitable polymers to inhibit humidity-induced solid-state crystallization of lacidipine amorphous solid dispersions.
Sun M; Wu C; Fu Q; Di D; Kuang X; Wang C; He Z; Wang J; Sun J
Int J Pharm; 2016 Apr; 503(1-2):238-46. PubMed ID: 26869398
[TBL] [Abstract][Full Text] [Related]
56. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique.
Chauhan B; Shimpi S; Paradkar A
Eur J Pharm Sci; 2005 Oct; 26(2):219-30. PubMed ID: 16087324
[TBL] [Abstract][Full Text] [Related]
57. [Study on the properties of felodipine solid dispersions prepared by different technologies].
Shi NQ; Zhang H; Zhang Y; Feng B; Li ZQ; Qi XR
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1067-1073. PubMed ID: 27987515
[TBL] [Abstract][Full Text] [Related]
58. Enhancing solubility and bioavailability of coenzyme Q
Lamichhane S; Seo JE; Keum T; Noh G; Bashyal S; Cho SW; Lee EH; Lee S
Arch Pharm Res; 2022 Jan; 45(1):29-37. PubMed ID: 35128573
[TBL] [Abstract][Full Text] [Related]
59. An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing.
Alhijjaj M; Belton P; Qi S
Eur J Pharm Biopharm; 2016 Nov; 108():111-125. PubMed ID: 27594210
[TBL] [Abstract][Full Text] [Related]
60. Hot melt extrusion of heat-sensitive and high melting point drug: Inhibit the recrystallization of the prepared amorphous drug during extrusion to improve the bioavailability.
Huang D; Xie Z; Rao Q; Liamas E; Pan P; Guan S; Zhang ZJ; Lu M; Li Q
Int J Pharm; 2019 Jun; 565():316-324. PubMed ID: 31022504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
